Skip to main content
. 2013 Dec 10;4:182–189. doi: 10.1016/j.nicl.2013.12.001

Fig. 5.

Fig. 5

In MS patients receiving immunomodulatory treatment, we found the number of days since onset of last relapse to be a significant predictor of permeability in MS non-enhancing lesions (A), and periventricular normal appearing white matter (B). In the untreated group we found no such relation. Data points = mean value for each subject. Continuous line = logarithmic fit line; y = a − b∗log(x). R sq = R2. IFN-beta = interferon beta. GA = glatiramer acetate.